This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
Well that’s a shake up ….. The UK Index pays out a whopping 40 points for ex-dividends and then falls another 200 points to finish the week lower as North Korea and Trump flex their muscles over Guam!
Major markets around the world has only just have been trading around record highs, but with political tensions ramping up my clients are asking just one thing? ‘What do you buy at a time like this?’’
Where can I find discounted stocks, with good dividends, good growth potential, and with global demand even amid geopolitical (thankfully not yet nuclear) turmoil?
How about the Pharmaceuticals trio I like to refer to as ‘GAS’ – Glaxo, Astra & Shire
GlaxoSmithKline, AstraZeneca, and Shire are trading around 2017 lows having fallen 15-25% their 2017 peaks . Everyone loves a takeover story, and this sector is rife with speculation. Ever since US giant Pfizer bid for Astra and AbbVie tried to marry up with Shire.
The majority of broker calls from the big investment banks have been extremely bullish. Shire, for example, has been tipped by analysts to rally by 40% over the next twelve months. Add to this dividend yields of up to 5.4% and a sector that will always benefit from global demand ……. Where else would you look right now?
If you’d like a report with more details about these pharmaceutical companies get access here or, better still, get in touch with me directly on the trading desk.
James Abbot, Senior Trader, 11 Aug 2017 [email protected]
If this has been a tough week for your shares …… just remember the football season is back!!!! Come on you West Ham!
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research
Comments are closed.